Company Profile
Intensity Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Intensity Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Intensity Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Intensity Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Intensity Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
INTS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Intensity Therapeutics’ catalysts are INT230-6 and the oncology programs, where each clinical update can affect how the market sees the platform. The company still needs stronger human proof.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Source: Intensity Therapeutics
- 02
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Source: Intensity Therapeutics
- 03
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Source: Intensity Therapeutics
- 04
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Source: Intensity Therapeutics
- 05
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Source: Intensity Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.